TRECONDI® (treosulfan) by medac received EU-wide approval for toxicity-reducing conditioning therapy prior to allogeneic haematopoietic stem cell transplantation

medac was granted a marketing authorisation by the European Commission for TRECONDI® (treosulfan), as part of conditioning treatment prior to alloHSCT in adult patients with malignant and non-malignant diseases and in paediatric patients with malignant diseases

Wedel (25 June 2019). German pharmaceutical company medac Gesellschaft für klinische Spezialpräparate mbH today announced that the European Commission (EC) has granted marketing authorisation for TRECONDI® (treosulfan) in combination with fludarabine as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases and in paediatric patients older than one month with malignant diseases. The EC approval is essentially based on data from the pivotal Phase 3 study MC-FludT.14/L-Part II¹ and the Phase 2 study MC-FludT.17/M². The successful development and approval of this new toxicity-reduced conditioning regimen with TRECONDI® strengthens medac’s position in the field of haematology. The decision takes effect for all 28 EU Member States plus Liechtenstein, Iceland, and Norway where TRECONDI® is about to be launched.

¹ EU Clinical Trials Register, Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens. EudraCT Number: 2008-002356-18.

² EU Clinical Trials Register, Clinical phase II trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies. EudraCT Number: 2013-003604-39.
Press Release

25.06.2019

Conditioning with treosulfan – clinically relevant survival benefit

Allogeneic haematopoietic stem cell transplantation (alloHSCT) is the only potentially curative treatment option for many malignant and non-malignant diseases. It is imperative that transplantation be preceded by preparatory conditioning therapies. The standard in this respect is conditioning with high-dose, toxic myeloablative regimes which, however, are not suitable for numerous at-risk groups. For some time now, research has therefore been conducted into so-called reduced-intensity conditioning therapies. With the treosulfan-based reduced-toxicity conditioning (RTC) by medac, such a new therapy option is approved now Europe-wide. The treosulfan-based treatment is characterised by a high level of intensity and antileukaemic effect comparable to that of the myeloablative regimes with considerably reduced toxicity at the same time.

The approval takes into account the current study data for TRECONDI®, register data as well as the extensive literature and confirmes the efficacy and safety of the treosulfan-based conditioning regimen with its low toxicity profile. This will benefit at-risk groups in particular, who are excluded from the myeloablative regimens.

MC-FludT.14/L-Part II Phase 3 study on adult patients

The MC-FludT.14/L study to date is the largest international prospective Phase 3 study on conditioning treatment with treosulfan. It investigated a treosulfan/fludarabine-based conditioning regimen with $3 \times 10^{-5}$ g/m² treosulfan as an alternative to reduced-intensity conditioning therapy with busulfan/fludarabine in 570 predominantly elderly patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), who sometimes had comorbidities, and for whom allogeneic HSCT was indicated. In addition to the early achievement of the primary endpoint, the study notably yielded excellent results for the secondary endpoints, particularly in terms of survival. For example, event-free survival (EFS) in the treosulfan group after 2 years was significantly higher at 65.7% than 51.2% for the busulfan-based control group.

---

9. The median age of patients was 60 years (range 31–70 years), 25% of patients were older than 65 years. 64% of patients had AML and 36% MDS.

10. Beelen, DW et al., Final Results of a Prospective Randomized Multicenter Phase III Trial Comparing Treosulfan / Fludarabine to Reduced Intensity Conditioning with Busulfan / Fludarabine Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Elderly or Comorbid Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Blood. 2017;130 (Suppl 1):521. URL: http://www.bloodjournal.org/content/130/Suppl_1/521 (Stand: 25.06.2019).


At the same time, overall survival (OS) on the treosulfan-based regimen was also considerably higher than in the busulfan comparator arm, at 72.7% vs. 60.2%. The conditioning therapy with treosulfan-based regimen for MDS and AML thus shows a survival rate of more than 70% after two years.

**Effective and well-tolerated in adult patients with non-malignant diseases**

The treosulfan-based conditioning regimen also results in highly favourable outcomes when used for other indications, although the data are not so extensive available on treosulfan-based conditioning in adult patients with non-malignant disorders (NMD).\textsuperscript{14,15,16,17} The main indications for an alloHSCT


\textsuperscript{15} Bernardo ME et al., Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 2012;120:473-476.
with treosulfan conditioning in adult NMD patients are haemoglobinopathies (e.g. sickle cell disease, thalassaemia major and Fanconi’s anaemia), primary immune deficiency, hemophagocytic disorder, immune dysregulatory disorder and bone marrow failure.

**MC-FludT.17/M Phase 2 study** on paediatric patients

A Phase 2 study with 70 paediatric patients aged from 28 days to 18 years also confirmed the high level of efficacy and safety of conditioning with treosulfan in children with malignant blood diseases. In particular, the good results regarding the non-relapse mortality rate (NRM) favour the use of treosulfan-based conditioning therapy in children. The maximum conditional cumulative engraftment rate of 100% is excellent. In this study 98.6% reached the primary endpoint freedom from transplant-related mortality (TRM) 100 days after HSCT.

**Treosulfan – About the active substance and mode of action**

The active compound treosulfan is a prodrug and belongs to the group of bifunctional alkylating agents. Despite its structural similarity to busulfan, the treosulfan molecule shows a different mechanism of action due to its two hydroxyl groups. Under physiological conditions, an enzyme-independent intramolecular nucleophilic substitution takes place. Formation of an epoxide ring results in the elimination of two methane sulphonic acid molecules. The resulting molecules (1,2-epoxy-3,4-butanediol-4-methane sulfonate and L-diepoxybutane) are to be regarded as the chemically effective reaction products which bind to biological macromolecules and trigger the antiproliferative and cytotoxic effect.

---


18 Kalwak, K et al. Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies. Blood. 2018;132 (Suppl 1):3354. URL: http://www.bloodjournal.org/content/132/Suppl_1/3354 (Stand: 25.06.2019).
Press Release

25.06.2019

Media contact

Press Officer
Volker Bahr
Tel. +49 (0)4103 – 8006 9111
Fax +49 (0)4103 – 8006 8934
mail@press.de

medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstraße 6
D – 22880 Wedel
www.medac.de

medac Gesellschaft für klinische Spezialpräparate mbH
medac is a privately-owned German pharmaceutical company with sites in Wedel and Tornesch. medac’s medicinal products are used worldwide to help doctors and patients manage acute and chronic diseases in the fields of oncology and haematology, urology, and autoimmune diseases. medac also develops and distributes specialist diagnostic systems. Since 1970, medac has been committed to its approach of uniting therapeutic and diagnostic products under one roof. Further information on the company and its products can be found online at www.medac.de.